CD4 and non-small cell lung carcinoma: The study objectives were to assess the clinical efficacy, immune function (including CD3+, CD4+, CD8+, CD4+/CD8+, natural killer (NK) cell count, IgA, IgG, and IgM), adverse events such as nausea and vomiting, thrombocytopenia, and leukopenia of combination therapy in patients with advanced NSCLC (Figure 1).